- Record: found
- Abstract: found
- Article: found
Angiotensin Analogs: Effect of Prostaglandin Synthesis Inhibitor
M.M. Hall , S. Gurchinoff , M.C. Khosla , P.A. Khairallah
18 September 2008
Ang II, Rabbit aorta, Binding, Sari, Thr8 Ang II, Indomethacin, ETYA, Contraction
Read this article at
Abstract
Structurally different inhibitors of prostaglandin synthesis reversed the antagonistic activity of the angiotensin II analog 1-sarcosine, 8-threonine angiotensin II. In isolated rabbit aorta, indomethacin or ETYA (eicosa 5, 8, 11, 14, tetraynoic) reversed the antagonism of the angiotensin II analog without affecting the dose response curves to angiotensin II. Both indomethacin and ETYA were able to reverse the tachyphylaxis to angiotensin II. Investigating the possibility that indomethacin could affect the binding of angiotensin II, it was found that at doses of indomethacin higher than 10<sup>–5</sup> m, binding of tritiated angiotensin to isolated adrenal cortical cells was reduced. It is postulated that indomethacin may have more than one effect on angiotensin, possessing a concentration-dependent effect on binding and prostaglandin synthesis.
Related collections
Author and article information
Journal
Affiliations
Article
158175 Blood Vessels 1978;15:299–310Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.